Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.

In a report released today, Eliana Merle from Barclays maintained a Hold rating on Sagimet Biosciences, Inc. Class A, with a price target of $8.00....

Barclays Sticks to Their Hold Rating for Sagimet Biosciences, Inc. Class A (SGMT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Korro Bio (KRRO – Research Report), Sagimet Biosci...

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perspective Therapeutics (CATX – Research Report), M...

Wall Street Analysts Are Bullish on Top Healthcare Picks

An update from Sagimet Biosciences, Inc. Class A ( ($SGMT) ) is now available. Sagimet Biosciences reported its fourth-quarter and full-year 2025 r...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGMT	$5.60	+10.22%	442.69K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SGMT	$5.60	+10.2%	442.69K
3
4
5
6

SGMT

SGMT

Get Sagimet Biosciences Inc. Data in Excel

Get Sagimet Biosciences Inc. Data in Excel